Transthyretin Amyloidosis Outcome Survey (THAOS) (THAOS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00628745|
Recruitment Status : Recruiting
First Posted : March 5, 2008
Last Update Posted : July 11, 2022
|Condition or disease||Intervention/treatment|
|Transthyretin Gene Mutations Transthyretin Amyloidosis||Other: None. Observational Study.|
|Study Type :||Observational|
|Estimated Enrollment :||8000 participants|
|Official Title:||Transthyretin Amyloidosis Outcomes Survey (THAOS): A Global, Multi-Center, Longitudinal, Observational Survey of Patients With Documented Transthyretin Gene Mutations or Wild-Type Transthyretin Amyloidosis.|
|Actual Study Start Date :||January 4, 2008|
|Estimated Primary Completion Date :||June 16, 2023|
|Estimated Study Completion Date :||June 16, 2023|
Other: None. Observational Study.
- The objectives of THAOS are to describe the population of patients affected with TTR amyloidosis and to enhance the understanding of the disease natural history, including the variability and progression of the hereditary and acquired forms of disease. [ Time Frame: Dec 2007 to June 2023 ]Cardiovascular and Neurological efficacy endpoints for analysis of clinical outcomes on all enrolled patients with available data. Outcomes will be examined for the entire patient group, as well as through subgroups based on important variables.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00628745
|Contact: Pfizer CT.gov Call Center||1-800-718-1021||ClinicalTrials.gov_Inquiries@pfizer.com|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|